Similarly, ACS patients administered with the IL-6 inhibitor tocilizumab showed a reduced level of troponin and inflammatory markers in the ASSessing the Effect of Anti-IL-6 Treatment in MI (ASSAIL-MI) trial [16, 69, 70], which was designed to assess the effects of tocilizumab on ischemia reperfusion injury in patients with ST-elevation myocardial infarction. This evidence concerns the gene IL6 and ST Elevation Myocardial Infarction.